EBERSBERG, Germany – Eurofins Genomics (Paris:ERF), Eurofins BioDiagnostics and Medicinal Genomics Corp (MGC), introduced the formal launch of economic SNP genotyping companies for hemp and medicinal hashish breeders. The newly launched CannSNP90 genotyping assay relies on industry-leading array platforms and will assist clients with their efforts to develop hemp and hashish cultivars that exhibit particular chemical profiles and illness resistant traits.
This new assay is meant to supply the most effective genetic resolution for shoppers, serving to them revolutionize breeding, genetic purity, and assist IP round hemp and hashish strains. Eurofins Genomics and Medicinal Genomics are amongst the premier suppliers of genetic evaluation options for detection of genetic traits.
The chip was developed utilizing Kannapedia®, the world’s largest hashish genomic database accessible via Medicinal Genomics, leveraging over 75,000 distinctive genetic options. Along with tens of hundreds of high-impact coding SNPs, there are markers for 39 cannabinoid genes, plant intercourse, chemotypes (I-IV), and illness resistance captured on the array. These traits are crucial available in the market. The knowledge from the chip may be additional analyzed utilizing Kannapedia to collect inhabitants frequencies, Bt:Bd allele protection, heterozygosity, relatedness to different cultivars and different genetic data within the database.
This product has the potential for not simply breeding, authentication and genotyping functions but additionally for additional analysis within the area, finally serving to clients convey to market protected and additionally revolutionary merchandise.
A one-hour webinar on functions and use of the chip is deliberate for November 2020. Companies interested by studying extra can register at: https://www.eurofinsus.com/biodiagnostics/resources/webinars/cannsnp90
The CannSNP90 chip is now accessible for orders.
With over 50,000 employees throughout a community of greater than 800 laboratories in over 50 nations, Eurofins’ corporations provide a portfolio of over 200,000 analytical strategies. Eurofins Shares are listed on Euronext Paris Stock Exchange.
About Medicinal Genomics Corporation
Medicinal Genomics Corporation is a pioneer in advancing the genomics of hashish to construct a stronger scientific basis for cannabis-based merchandise. The firm’s unmatched experience in genetic science helps clients characterize and perceive the standard and consistency of hashish to make sure sufferers and shoppers entry to persistently protected, prime quality hashish. For extra info, please go to www.medicinalgenomics.com.